Back to mobile site

More on ALZN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (12/12/25 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Alzamend Neuro (NQ:ALZN)
Delayed: 1.21 +0.06 (5.22%)
Prev. Close $1.15  
Open$1.13 
52 Wk High$ 
52 Wk Low$ 
Day High$1.24 
Day Low$1.13 
P/E N/A  
EPS$ 
Volume61,212 


Apr 17, 2026 04:31 PM Form 8-K Alzamend Neuro, Inc. For: Apr 17
Apr 16, 2026 04:30 PM Form 4 Alzamend Neuro, Inc. For: Apr 14 Filed by: AULT MILTON C III
Apr 7, 2026 12:37 PM Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Apr 7, 2026 08:07 AM Alzamend Neuro reports early brain study data for AL001 compound
Mar 26, 2026 08:02 AM Alzamend Neuro reports AL001 meets bioequivalence in phase II trial
Mar 26, 2026 08:01 AM Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All
Mar 20, 2026 04:31 PM Form 8-K Alzamend Neuro, Inc. For: Mar 20
Mar 16, 2026 08:02 AM Alzamend Neuro starts phase II trial of AL001 for bipolar disorder
Mar 16, 2026 08:00 AM Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Mar 11, 2026 04:32 PM Form 10-Q Alzamend Neuro, Inc. For: Jan 31
View All Articles

Entities mentioned with ALZN

View All Entities